1. Home
  2. ITRM vs ASLE Comparison

ITRM vs ASLE Comparison

Compare ITRM & ASLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITRM
  • ASLE
  • Stock Information
  • Founded
  • ITRM 2015
  • ASLE 2008
  • Country
  • ITRM Ireland
  • ASLE United States
  • Employees
  • ITRM N/A
  • ASLE N/A
  • Industry
  • ITRM Biotechnology: Pharmaceutical Preparations
  • ASLE Industrial Specialties
  • Sector
  • ITRM Health Care
  • ASLE Consumer Discretionary
  • Exchange
  • ITRM Nasdaq
  • ASLE Nasdaq
  • Market Cap
  • ITRM 35.6M
  • ASLE N/A
  • IPO Year
  • ITRM 2018
  • ASLE N/A
  • Fundamental
  • Price
  • ITRM $1.26
  • ASLE $6.88
  • Analyst Decision
  • ITRM Strong Buy
  • ASLE Strong Buy
  • Analyst Count
  • ITRM 1
  • ASLE 3
  • Target Price
  • ITRM $5.00
  • ASLE $9.00
  • AVG Volume (30 Days)
  • ITRM 384.2K
  • ASLE 550.1K
  • Earning Date
  • ITRM 05-12-2025
  • ASLE 05-07-2025
  • Dividend Yield
  • ITRM N/A
  • ASLE N/A
  • EPS Growth
  • ITRM N/A
  • ASLE N/A
  • EPS
  • ITRM N/A
  • ASLE 0.11
  • Revenue
  • ITRM N/A
  • ASLE $345,066,000.00
  • Revenue This Year
  • ITRM N/A
  • ASLE $14.51
  • Revenue Next Year
  • ITRM $150.10
  • ASLE $18.41
  • P/E Ratio
  • ITRM N/A
  • ASLE $61.36
  • Revenue Growth
  • ITRM N/A
  • ASLE 3.16
  • 52 Week Low
  • ITRM $0.81
  • ASLE $4.53
  • 52 Week High
  • ITRM $3.02
  • ASLE $9.40
  • Technical
  • Relative Strength Index (RSI)
  • ITRM 52.72
  • ASLE 45.72
  • Support Level
  • ITRM $1.21
  • ASLE $6.38
  • Resistance Level
  • ITRM $1.42
  • ASLE $6.62
  • Average True Range (ATR)
  • ITRM 0.09
  • ASLE 0.34
  • MACD
  • ITRM 0.03
  • ASLE -0.02
  • Stochastic Oscillator
  • ITRM 60.98
  • ASLE 49.29

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: